μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release

C. Fimiani, E. Arcuri, A. Santoni, C. M. Rialas, T. V. Bilfinger, D. Peter, B. Salzet, G. B. Stefano

Research output: Contribution to journalArticlepeer-review

Abstract

The μ3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the μ3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific μ opioid receptor transcripts are present in lung carcinoma and other cells with the μ3 profile. Our findings identify a unique role for the μ3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalCancer Letters
Volume146
Issue number1
DOIs
Publication statusPublished - Nov 1 1999

Keywords

  • μ
  • Alternative splicing
  • Cancer
  • Lung
  • Morphine
  • Neoplasia
  • Nitric oxide
  • Opioid receptor transcript

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Fingerprint Dive into the research topics of 'μ3 Opiate receptor expression in lung and lung carcinoma: Ligand binding and coupling to nitric oxide release'. Together they form a unique fingerprint.

Cite this